Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer

Personalized medicine: Mutated tumors respond to therapy Mutations in the p53 tumor suppressor gene could offer a predictive biomarker of response to certain drugs in triple-negative breast cancer. Jill Bargonetti from Hunter College in New York, USA, and colleagues showed that mutant p53, which is...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wei-Gang Qiu, Alla Polotskaia, Gu Xiao, Lia Di, Yuhan Zhao, Wenwei Hu, John Philip, Ronald C. Hendrickson, Jill Bargonetti
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b2c5b334b48243aca21c4d45cdb91aa3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b2c5b334b48243aca21c4d45cdb91aa3
record_format	dspace
spelling	oai:doaj.org-article:b2c5b334b48243aca21c4d45cdb91aa32021-12-02T15:18:47ZIdentification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer10.1038/s41523-016-0001-72374-4677https://doaj.org/article/b2c5b334b48243aca21c4d45cdb91aa32017-01-01T00:00:00Zhttps://doi.org/10.1038/s41523-016-0001-7https://doaj.org/toc/2374-4677Personalized medicine: Mutated tumors respond to therapy Mutations in the p53 tumor suppressor gene could offer a predictive biomarker of response to certain drugs in triple-negative breast cancer. Jill Bargonetti from Hunter College in New York, USA, and colleagues showed that mutant p53, which is expressed in more than 80% of patients with triple-negative breast cancer, interacts with and regulates hundreds of proteins, including those found in a complex needed for DNA replication. Members of this complex, called the minichromosome maintenance protein complex, interact with mutant p53—but less with wild-type p53. Bargonetti’s team targeted this pathway in mutated breast cancer cells with the PARP inhibitor talazoparib and the chemotherapeutic agent temozolomide. They observed synergistic cell killing with the two drugs, but only when the minichromosome maintenance protein complex was working and when p53 was mutated. These findings point toward a new strategy for personalizing therapy.Wei-Gang QiuAlla PolotskaiaGu XiaoLia DiYuhan ZhaoWenwei HuJohn PhilipRonald C. HendricksonJill BargonettiNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 3, Iss 1, Pp 1-9 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Wei-Gang Qiu Alla Polotskaia Gu Xiao Lia Di Yuhan Zhao Wenwei Hu John Philip Ronald C. Hendrickson Jill Bargonetti Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
description	Personalized medicine: Mutated tumors respond to therapy Mutations in the p53 tumor suppressor gene could offer a predictive biomarker of response to certain drugs in triple-negative breast cancer. Jill Bargonetti from Hunter College in New York, USA, and colleagues showed that mutant p53, which is expressed in more than 80% of patients with triple-negative breast cancer, interacts with and regulates hundreds of proteins, including those found in a complex needed for DNA replication. Members of this complex, called the minichromosome maintenance protein complex, interact with mutant p53—but less with wild-type p53. Bargonetti’s team targeted this pathway in mutated breast cancer cells with the PARP inhibitor talazoparib and the chemotherapeutic agent temozolomide. They observed synergistic cell killing with the two drugs, but only when the minichromosome maintenance protein complex was working and when p53 was mutated. These findings point toward a new strategy for personalizing therapy.
format	article
author	Wei-Gang Qiu Alla Polotskaia Gu Xiao Lia Di Yuhan Zhao Wenwei Hu John Philip Ronald C. Hendrickson Jill Bargonetti
author_facet	Wei-Gang Qiu Alla Polotskaia Gu Xiao Lia Di Yuhan Zhao Wenwei Hu John Philip Ronald C. Hendrickson Jill Bargonetti
author_sort	Wei-Gang Qiu
title	Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
title_short	Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
title_full	Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
title_fullStr	Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
title_full_unstemmed	Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
title_sort	identification, validation, and targeting of the mutant p53-parp-mcm chromatin axis in triple negative breast cancer
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/b2c5b334b48243aca21c4d45cdb91aa3
work_keys_str_mv	AT weigangqiu identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer AT allapolotskaia identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer AT guxiao identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer AT liadi identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer AT yuhanzhao identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer AT wenweihu identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer AT johnphilip identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer AT ronaldchendrickson identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer AT jillbargonetti identificationvalidationandtargetingofthemutantp53parpmcmchromatinaxisintriplenegativebreastcancer
_version_	1718387468952141824

Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer

Ejemplares similares